Revenue
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Aethlon Medical Inc (AEMD)
Price$6.31Cached quote
Net income
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Free cash flow
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Total cash / debt
CashTotal debt
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Financial statements
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $574,245 | $294,165 | $659,104 | $650,187 | $229,625 | $149,625 | $392,073 | $886,572 | $762,417 | $1.6M | $1.2M | $1.4M | — |
| Research & development | $1.9M | $2.2M | $2.5M | $2.7M | $2.3M | $2.1M | $927,000 | $896,000 | $586,000 | $673,000 | $782,000 | $1.0M | $1.5M | $1.4M | — | — |
| Operating expenses | $7.3M | $9.3M | $12.6M | $12.5M | $10.7M | $8.6M | $6.6M | $6.2M | $5.0M | $6.5M | $5.3M | $4.8M | $4.7M | $4.8M | $4.5M | $4.6M |
| Operating income | −$7.3M | −$9.3M | −$12.6M | −$11.9M | −$10.4M | −$7.9M | −$5.9M | −$6.0M | −$4.8M | −$6.1M | −$4.4M | −$4.0M | −$3.1M | −$3.6M | −$3.1M | −$4.6M |
| Operating margin | — | — | — | −2,072.05% | −3,542.53% | −1,197.31% | −912.04% | −2,612.53% | −3,228.82% | −1,555.41% | −494.58% | −523.71% | −188.20% | −290.68% | −229.06% | — |
| EBITDA | −$7.0M | −$9.0M | −$12.3M | −$11.7M | −$10.3M | −$7.9M | −$5.9M | −$6.0M | −$4.8M | −$6.1M | −$4.3M | −$4.0M | −$3.0M | −$3.6M | −$3.1M | −$4.5M |
| EBITDA margin | — | — | — | −2,030.10% | −3,500.48% | −1,191.25% | −907.99% | −2,599.16% | −3,204.98% | −1,547.15% | −490.24% | −518.81% | −186.90% | −289.83% | −227.79% | — |
| Net income | −$7.2M | −$13.4M | −$12.2M | −$12.0M | −$10.4M | −$7.9M | −$6.4M | −$6.2M | −$5.7M | −$7.3M | −$4.9M | −$6.8M | −$13.4M | −$4.9M | −$8.1M | −$5.7M |
| Net profit margin | — | — | — | −2,094.89% | −3,540.90% | −1,196.58% | −980.33% | −2,697.75% | −3,795.86% | −1,855.81% | −549.57% | −891.53% | −822.61% | −397.73% | −596.59% | — |
| Basic EPSper basic share | -$53.05 | -$428.85 | -$194.35 | -$234.40 | -$284.00 | -$260.00 | -$748.00 | -$2,052.00 | -$600.00 | -$5,640.00 | -$3,960.00 | -$7,320.00 | -$20,640.00 | -$9,000.00 | -$24,000.00 | -$24,000.00 |
| Diluted EPSper diluted share | -$53.05 | -$428.85 | -$194.35 | -$234.40 | -$284.00 | -$260.00 | -$748.00 | -$2,052.00 | -$600.00 | -$5,640.00 | -$3,960.00 | -$7,320.00 | -$20,640.00 | -$9,000.00 | -$24,000.00 | -$24,000.00 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
Rossetti Angela | 26.21K |
BROENNIMAN EDWARD G | 23.45K |
Shah Chetan | 23.02K |
Gikakis Nicolas | 22.84K |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
Community posts
Aethlon agrees to North Immunology merger backed by $180 million financing
Aethlon ($AEMD) Medical agreed to an all-stock merger with North Immunology, accompanied by a private placement described as approximately $180 million in gross proceeds. That amount includes the conversion of roughly $34 million of existin ...
